RT Journal
A1 Farag N, Burns R, Come SE
T1 Update: A 62-year-old woman with a new diagnosis of breast cancer
JF JAMA
JO JAMA
YR 2008
FD March 5
VO 299
IS 9
SP 1055
OP 1056
DO 10.1001/jama.299.9.1055
UL http://dx.doi.org/10.1001/jama.299.9.1055
AB 
Ms T was considered a good candidate for breast conservation therapy and underwent a wire localized excisional biopsy in November 2004. Final pathological findings revealed an infiltrating lobular carcinoma with an invasive component of 9 mm and a histologic grade of 2 (out of 3). Given her good prognosis, age, and positive estrogen and progesterone receptors, she underwent radiation treatment to the left breast and was prescribed tamoxifen. Ms T wondered whether an aromatase inhibitor (AI) would be superior to the tamoxifen. Dr Come recommended that Ms T undergo sequential therapy, first taking tamoxifen for 2 to 3 years and then switching to an AI. He believed that over the next several years, additional safety data about AIs would become available to help guide future treatment decisions.